FLKS vs. GRAY, CYCN, OBSV, TRVN, VAXX, BNOX, CANF, EFTR, OGEN, and VIRI
Should you be buying Flex Pharma stock or one of its competitors? The main competitors of Flex Pharma include Graybug Vision (GRAY), Cyclerion Therapeutics (CYCN), ObsEva (OBSV), Trevena (TRVN), Vaxxinity (VAXX), Bionomics (BNOX), Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), Oragenics (OGEN), and Virios Therapeutics (VIRI). These companies are all part of the "medical" sector.
Graybug Vision (NASDAQ:GRAY) and Flex Pharma (NASDAQ:FLKS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
Flex Pharma has higher revenue and earnings than Graybug Vision.
49.9% of Graybug Vision shares are owned by institutional investors. Comparatively, 14.4% of Flex Pharma shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by company insiders. Comparatively, 7.6% of Flex Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Graybug Vision has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Flex Pharma has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
In the previous week, Graybug Vision had 1 more articles in the media than Flex Pharma. MarketBeat recorded 1 mentions for Graybug Vision and 0 mentions for Flex Pharma. Flex Pharma's average media sentiment score of 0.58 beat Graybug Vision's score of 0.00 indicating that Graybug Vision is being referred to more favorably in the media.
Flex Pharma received 345 more outperform votes than Graybug Vision when rated by MarketBeat users. Likewise, 73.23% of users gave Flex Pharma an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote.
Graybug Vision has a net margin of 0.00% compared to Graybug Vision's net margin of -1,208.42%. Flex Pharma's return on equity of -77.61% beat Graybug Vision's return on equity.
Summary
Graybug Vision beats Flex Pharma on 7 of the 12 factors compared between the two stocks.
Get Flex Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FLKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Flex Pharma Competitors List
Related Companies and Tools
